|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2020
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contraindication
|
severe allergic reaction to vaccine component
|
|
gptkbp:developedBy
|
gptkb:COVID-19
|
|
gptkbp:distribution
|
global
|
|
gptkbp:doseRegimen
|
single dose
booster dose
two doses
|
|
gptkbp:effect
|
reduces risk of severe COVID-19
|
|
gptkbp:emergencyServices
|
granted in many countries
|
|
gptkbp:example
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
gptkb:Pfizer–BioNTech_COVID-19_vaccine
gptkb:Covaxin
gptkb:Johnson_&_Johnson_COVID-19_vaccine
gptkb:Moderna_COVID-19_vaccine
gptkb:Sinopharm_BIBP_COVID-19_vaccine
gptkb:Sinovac_COVID-19_vaccine
gptkb:Sputnik_V
|
|
gptkbp:fundedBy
|
international organizations
governments
pharmaceutical companies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
COVID-19 vaccines
|
|
gptkbp:monitors
|
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:World_Health_Organization
national health agencies
|
|
gptkbp:publicHealthConcern
|
reduced COVID-19 mortality
reduced COVID-19 transmission
reduced hospitalization rates
|
|
gptkbp:recommendation
|
adults
children (some vaccines)
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
chills
injection site pain
|
|
gptkbp:storage
|
refrigeration
ultra-cold storage (for some types)
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:type
|
vaccine
viral vector vaccine
inactivated virus vaccine
protein subunit vaccine
|
|
gptkbp:bfsParent
|
gptkb:Novavax_COVID-19_vaccine
gptkb:FDA
gptkb:mRNA_vaccine_technology
gptkb:COVID-19_Vaccination
|
|
gptkbp:bfsLayer
|
5
|